ERJ Advances: Home Monitoring in Interstitial Lung Disease

02 Apr 20264 min read0 viewsJournal Feed

GIST

Extract Interstitial lung diseases (ILDs) encompass a heterogeneous group of inflammatory and fibrotic conditions. The ILD diagnostic ontology based on morphological features of radiology and histopathology with identification of secondary aetiologies has evolved over the past decades, forming the basis of patient care [1 - 3].

Besides the diagnostic label, importance of disease behaviour in ILD care is well-established, with the introduction of its classification in 2013 [2] and guidelines for progressive pulmonary fibrosis (PPF) more recently [4]. In addition, sporadic events, such as acute exacerbation of ILD [5], can accelerate the disease process.

Thus, serial monitoring is a core component in ILD care, with a multifaceted approach of symptom, physiological and radiological assessments. Existing monitoring strategies centre on scheduled periodic in-person evaluations.

This poses risks of delayed recognition of disease progression and subsequent treatment initiation, which may adversely impact patient outcomes. In addition, the growing prevalence of ILD globally raises concerns of difficulty accessing specialist care [6 - 9].

More flexible and patient-centred monitoring strategies are therefore needed.

Clinical Editorial

Title context and scope

The piece surveys interstitial lung diseases (ILDs) as a diverse group of inflammatory and fibrotic conditions, noting their evolving diagnostic framework based on radiologic and histopathologic features and the identification of secondary causes.

Study design and clinical landscape

The article highlights how disease behavior, beyond diagnostic labeling, informs ILD management, referencing 2013 classification developments and more recent guidelines for progressive pulmonary fibrosis.
It acknowledges episodic events such as acute exacerbations that can hasten disease progression and emphasizes the role of serial monitoring as a central aspect of care.

Current monitoring paradigm

Traditional monitoring relies on scheduled in-person assessments that may delay recognition of progression and hinder timely therapy initiation.
The global rise in ILD prevalence raises concerns about access to specialist care and the feasibility of frequent in-person visits.

Rationale for evolving strategies

There is a stated need for more flexible, patient-centered monitoring approaches to address delays in detecting progression and to improve accessibility of care.

Limitations and uncertainties

The provided content does not include specific data on outcomes, study designs, or quantitative results related to home monitoring or alternative strategies.